Masha V Poyurovsky
Masha Poyurovsky, PhD is Vice President and Head of Biology at PMV Pharmaceuticals, where she leads discovery, in vivo pharmacology, and translational research across the company’s oncology pipeline, including rezatapopt, a first-in-class small-molecule reactivator of Y220C-mutant p53. Dr. Poyurovsky guides scientific strategy from mechanistic biology through IND-enabling studies and biomarker-driven clinical translation.
Dr. Poyurovsky’s work integrates deep expertise in p53 biology with precision-oncology approaches. Prior to PMV, she held senior leadership roles at Kadmon Pharmaceuticals (now Sanofi), advancing multiple small-molecule and biologics programs into the clinic. Her academic training at Columbia University focused on the molecular regulation of p53 and cancer metabolism, forming the foundation for her translational career.
Abstracts this author is presenting:
